CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

Genes and Development

Volumn 28, Issue 16, 2014, Pages 1800-1814

  Huang, Chun Hao ^a,b,c   Lujambio, Amaia ^a,c   Zuber, Johannes ^c,d   Tschaharganeh, Darjus F ^a   Doran, Michael G ^a   Evans, Michael J ^a   Kitzing, Thomas ^a,c   Zhu, Nan ^a   de Stanchina, Elisa ^a   Sawyers, Charles L ^a   Armstrong, Scott A ^a   Lewis, Jason S ^a   Sherr, Charles J ^e   Lowe, Scott W ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CDK9; MYC; Oncogene addiction; RNAi screen; Transcription elongation

Indexed keywords

CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; DSB PHA 767491; MYC PROTEIN; PHA 767491; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENZYME INHIBITION; GENE EXPRESSION; GENE LIBRARY; GENE OVEREXPRESSION; GENETIC SCREENING; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION ELONGATION;

CDK9; MYC; ONCOGENE ADDICTION; RNAI SCREEN; TRANSCRIPTION ELONGATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 9; FEMALE; GENE EXPRESSION; GENE LIBRARY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION ELONGATION, GENETIC;

EID: 84906074303     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.244368.114     Document Type: Article

References (71)

1. Ashworth A., Bernards R. 2010. Using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol 2: a003327.
2. Barretina J., Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
3. Beroukhim R., Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J., Barretina J, Boehm JS, Dobson J, Urashima M, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
4. Bisgrove D. A, Mahmoudi T, Henklein P, Verdin E. 2007. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci 104: 13690-13695.
5. Bracken A. P, Dietrich N, Pasini D, Hansen KH, Helin K. 2006. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20: 1123-1136.
6. Chen R., Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V., Plunkett W. 2009. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113: 4637-4645.
7. Cho S. J, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B., Lee SK. 2010. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Cancer Lett 287: 196-206.
8. Coller H. A, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman R. N, Golub TR. 2000. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci 97: 3260-3265.
9. Conacci-Sorrell M., McFerrin L, Eisenman RN. 2014. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4: a014357.
10. Core L. J, Waterfall JJ, Lis JT. 2008. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322: 1845-1848.
11. Dalla-Favera R., Bregni M, Erikson J, Patterson D, Gallo RC, Croce C.M. 1982. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci 79: 7824-7827.
12. Dang C.V. 2012. MYC on the path to cancer. Cell 149: 22-35.
13. Dawson M. A, Prinjha RK, Dittmann A, Giotopoulos G, BantscheffM, ChanWI, RobsonSC, ChungCW, Hopf C, Savitski MM, et al. 2011. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529-533.
14. Delmore J. E, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E., Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
15. Eberhardy S. R, Farnham PJ. 2001. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J Biol Chem 276: 48562-48571.
16. Farazi P. A, DePinho RA. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
17. Fellmann C., Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M., Lai DY, Barbosa IA, Kwon JS, Guan Y, et al. 2013. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 5: 1704-1713.
18. Felsher D.W. 2010. MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 1: 597-604.
19. Flaherty K. T, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman J. A, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
20. Goga A., Yang D, Tward AD, Morgan DO, Bishop JM. 2007. Inhibition of CDK1 as a potential therapy for tumors overexpressing MYC. Nat Med 13: 820-827.
21. Gojo I., Zhang B, Fenton RG. 2002. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8: 3527-3538.
22. Hahntow I. N, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F., Peschel C, Decker T. 2004. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18: 747-755.
23. Hemann M. T, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C., Hannon GJ, Lowe SW. 2003. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 33: 396-400.
24. Holland J. P, Sheh Y, Lewis JS. 2009. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36: 729-739.
25. Holland J. P, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis J.S. 2010. 89Zr-DFO-J591 for immunoPET of prostatespecific membrane antigen expression in vivo. J Nucl Med 51: 1293-1300.
26. Holland J. P, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. 2012. Annotating MYC status with 89Zr-transferrin imaging. Nat Med 18: 1586-1591.
27. Hoshida Y., Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang D. Y, Villanueva A, Newell P, Ikeda K, Hashimoto M, et al. 2009. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392.
28. Jiang W., McDonald D, Hope TJ, Hunter T. 1999. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J 18: 5703-5713.
29. Kanazawa S., Soucek L, Evan G, Okamoto T, Peterlin BM. 2003. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 22: 5707-5711.
30. Kessler J. D, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al. 2012. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-353.
31. Kumar M. S, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M., Armenteros-Monterroso E, Lassailly F, Matthews N., Nye E, et al. 2012. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149: 642-655.
32. Kwiatkowski N., Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, et al. 2014. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature doi: 10.1038/nature13393.
33. Lam L. T, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M et al. 2001. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2: research0041-research0041.11.
34. Laurent-Puig P., Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G., Thomas G, Bioulac-Sage P, Zucman-Rossi J. 2001. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773.
35. Lee T. I, Young RA. 2013. Transcriptional regulation and its misregulation in disease. Cell 152: 1237-1251.
36. Lin C. J, Nasr Z, Premsrirut PK, Porco JA Jr, Hippo Y, Lowe SW, Pelletier J. 2012a. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Reports 1: 325-333.
37. Lin C. Y, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012b. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
38. Llovet J. M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
39. Lockwood W. W, Zejnullahu K, Bradner JE, Varmus H. 2012. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci 109: 19408-19413.
40. Loven J., Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner J. E, Lee TI, Young RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153: 320-334.
41. Luo J., Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
42. Lynch T. J, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska F. G, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
43. Montagnoli A., Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, et al. 2008. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 4: 357-365.
44. Nie Z., Hu G, Wei G, Cui K, Yamane A, ReschW, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
45. O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A., Dang CV. 2006. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 26: 2373-2386.
46. Okamoto H., Yasui K, Zhao C, Arii S, Inazawa J. 2003. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 38: 1242-1249.
47. Peterlin B. M, Price DH. 2006. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23: 297-305.
48. Rahl P. B, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp P. A, Young RA. 2010. c-Myc regulates transcriptional pause release. Cell 141: 432-445.
49. Romano G. 2013. Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. ISRN Oncol 2013: 305371.
50. Sabo A., Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli M. J, Bora P, Doni M, Verrecchia A, et al. 2014. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511: 488-492.
51. Schlosser I., Holzel M, Hoffmann R, Burtscher H, Kohlhuber F, Schuhmacher M., Chapman R, Weidle UH, Eick D. 2005. Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene 24: 520-524.
52. Schramek D., Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B., Fuchs E. 2014. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 343: 309-313.
53. Schuhmacher M., Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M., Bornkamm GW, Laux G, Polack A, Weidle UH, et al. 2001. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 29: 397-406.
54. Sciot R., Verhoeven G, Van Eyken P, Cailleau J, Desmet VJ. 1990. Transferrin receptor expression in rat liver: immunohistochemical and biochemical analysis of the effect of age and iron storage. Hepatology 11: 416-427.
55. Shachaf C. M, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S., Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117.
56. Shibata T., Aburatani H. 2014. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 11: 340-349.
57. Soucek L., Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
58. Soucek L., Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis A. N, Swigart LB, Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27: 504-513.
59. Toyoshima M., Howie HL, Imakura M, Walsh RM, Annis JE, Chang A. N, Frazier J, Chau BN, Loboda A, Linsley PS, et al. 2012. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci 109: 9545-9550.
60. Tschaharganeh D. F, Xue W, Calvisi DF, Evert M, Michurina TV, Dow L. E, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, et al. 2014. p53 dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell doi: 10.1016/j.cell.2014.05.051.
61. Vennstrom B., Sheiness D, Zabielski J, Bishop JM. 1982. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 3: 773-779.
62. Villanueva A., Hernandez-Gea V, Llovet JM. 2013. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 10: 34-42.
63. Walz S., Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L., Dumay-Odelot H, Karim S, Bartkuhn M, et al. 2014. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511: 483-487.
64. Wang S., Fischer PM. 2008. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 29: 302-313.
65. Yant S. R, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA. 2000. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25: 35-41.
66. Zeller K. I, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. 2003. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69.
67. Zhang X., Edwards JP, Mosser DM. 2009. The expression of exogenous genes in macrophages: obstacles and opportunities. Methods Mol Biol 531: 123-143.
68. Zhou Q., Li T, Price DH. 2012. RNA polymerase II elongation control. Annu Rev Biochem 81: 119-143.
69. Zuber J., McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ, Lowe SW. 2011a. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol 29: 79-83.
70. Zuber J., Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J., Weissmueller S, Fellmann C, Taylor MJ, et al. 2011b. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 25: 1628-1640.
71. Zuber J., Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D., Qi J, Blatt K, Wunderlich M, et al. 2011c. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.